The SPINRAZA® clinical trial programme included 346 patients aged from newborns to young adults with SMA who received SPINRAZA® for up to 5 years1

The SPINRAZA® study programme comprises multiple open-label and randomised controlled trials and an open-label extension study.1

CLICK ON A STUDY TO LEARN MORE

Claire

Claire
age 19* Later-onset SMA
treated with SPINRAZA®

*Age at time of photo shoot.

References:
1. SPINRAZA® Summary of Product Characteristics.